1. my source is the Yahoo page; shows 16 million sold; 2. however NO ONE can dispute insider (lack) buying; only 328,000 shares which is .003 of total o/s; and NONE bought since Nov. (five mos. ago); and some speculation that those buys were tied to CEFF hits. That is indisputable unless the SEC is not posting on a timely basis.
I post here because I have lost alot and so have friends who have tracked this co. My biggest mistake has been not following rule #1 of investing....is mgt. capable/talented. No matter how you slice/dice that question for DSCO you cannot come to a conclusion that this team is stellar from a business/investor standpoint. Hopefully someday Surfaxin will save many childrens lives so that the science can be upheld and sustained.
But from a pure Harvard Bus. Review....this would not be a top ten positive case study.
Thanks yadahaven, I see. That was the prior quarter of this current quarter. That was the quarter that our kids will be reading about in the history books; "the crash of 2008". I am not sure anyone was buying anything October and November, and anyone leveraged was selling all dead weight; DSCO being dead weight with it's April 17th review date. The insiders were buying in that quarter, as you mentioned. And though you ridicule their purchase, I think it was a heafty sum of money. These are insiders at Discovery Labs, not Merck; not exactly making the big bucks. Check out some of the other links posted. This quarter is showing more buys than sells.
Mr. J. Palarski, I really like your web source. I bookmarked it when you introduced it to the board a few weeks ago.
The other data point that shows institutions haven't been buying is the current stock price. If a number of institutions were taking positions of several hundred thousand shares each, it would drive this price up regardless of any "greedy hedge funds" or "market maker's manipulations", or "%$%^^&% shorts". It is DSCO's track record and useless management that is holding it down.
Name one other drug that has no efficacy or safety issues that cannot get ITSELF approved.
The only thing that has been holding up Surfaxin's approval for 5 years is lousy incompetent management.